Publications by authors named "Brent W Footer"
The presence of extracorporeal membrane oxygenation (ECMO) in addition to underlying critical illness can affect the pharmacokinetics and pharmacodynamics of drugs that are often required to treat this patient population. While ampicillin is the preferred agent for the treatment of susceptible Enterococcus faecalis infections, there are no in vivo pharmacokinetic studies regarding ampicillin dosing in patients receiving ECMO. This case report consists of two patients on venovenous ECMO with E.
View Article and Find Full Text PDFFidaxomicin to prevent recurrent : what will it cost in the USA and Canada?
JAC Antimicrob Resist
February 2023
Article Synopsis
- Recent guidelines suggest using fidaxomicin as the main treatment for a type of infection called CDI, instead of vancomycin.
- The study looked at how much it costs to use fidaxomicin compared to vancomycin in the US and Canada, focusing on preventing these infections from coming back.
- The findings showed that if fidaxomicin were priced below about $1140 USD or $860 CAD, it could save money in the long run by preventing these infections from recurring.
Background: Although most observational studies identify viral or bacterial pathogens in 50% or less of patients hospitalized with community-acquired pneumonia (CAP), we previously demonstrated that a multi-test bundle (MTB) detected a potential pathogen in 73% of patients. This study compares detection rates for potential pathogens with the MTB versus the Biofire® Pneumonia FilmArray® panel (BPFA) multiplex PCR platform and presents an approach for integrating BPFA results as a foundation for subsequent antibiotic stewardship (AS) activities.
Methods: Between January 2017 to March 2018, all patients admitted for CAP were enrolled.